🔥 Friday 28 August 2026 Fri, 28 Aug 2026

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Clime Capital Limited (ASX:CAM) reported a sharp turnaround for FY26, with net profit after tax soaring 236% to $10.29 million, driven by strong unrealised gains and a higher income portfolio. The company sustained its steady dividend payments and pressed ahead with an active share and convertible note buyback program.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

Energy Fuels Inc. has completed its acquisition of Australian Strategic Materials (ASM) through members’ and creditors’ schemes of arrangement, triggering ASM’s delisting from the ASX. Eligible ASM shareholders received a mix of Energy Fuels shares and cash, while optionholders were paid cash for their options.

FlexiRoam Limited (ASX:FRX) reported a statutory net profit after tax of $0.7 million for FY26, reversing a $2.0 million loss in FY25, driven by a pivot to higher-quality recurring revenue and operational discipline.

Castile Resources reveals a robust 2026 Scoping Study for its Rover 1 IOCG Project, projecting an 11-year underground mine life with five valuable metals driving strong economics and a staged development strategy.

OMG Group posted a 48% revenue increase to $6.13 million in FY26, achieving its highest-ever gross margin of 41% while expanding distribution into New Zealand and Southeast Asia.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Orcoda Limited reported a 26% reduction in net loss and a 23% rise in Annual Recurring Revenue, boosted by a new $8 million per annum multi-year contract with Wagner Corporation, setting the stage for SaaS expansion in FY27.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.

Waterco Limited delivered a robust turnaround in FY26 with net profit after tax soaring 61.6% to $15.5 million on modest revenue growth. The company expanded its Swimart franchise, advanced manufacturing insourcing, and boosted dividends to 20 cents per share fully franked.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

RooLife Group (ASX: RLG) reported a 268% jump in FY2026 revenue to nearly $10 million, driven by rapid growth in its own food and beverage products, including RLG Coffee in China. Despite this, the company recorded a $3.58 million net loss, weighed down by impairment charges and R&D investments in renewable energy.

Forrestania Resources secured near-unanimous shareholder approval for its acquisition of the Edna May Project and a $310 million capital raising, clearing the path to expand its gold footprint in Western Australia.

Finbar has completed settlement on a prime South Perth development site with an estimated end value of $402 million, adding scale and strategic depth to its $1.95 billion five-year pipeline.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Elixir Energy has marked FY26 with major progress in Queensland’s Taroom Trough, expanding contingent gas resources by 32% and securing a strategic $16.6 million capital raise led by Omega Oil and Gas. The company’s operational advances and government backing position it as a key player in Australia’s energy security landscape.

Austral Resources Australia Ltd has swung from a $24.2 million loss to a $25.3 million profit in the first half of 2026, boosted by strategic acquisitions, capital raises, and operational shifts. The company is advancing its Rocklands restart and has proposed acquiring Hammer Metals to expand its copper footprint.

PhosCo Ltd has achieved a metallurgical breakthrough at its Gasaat Phosphate Project, producing premium-grade phosphate concentrate with a simplified flotation process, potentially unlocking significant price premiums.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Locality Planning Energy (ASX:LPE) reversed losses to post a $2.31 million statutory profit in FY2026, driven by strategic acquisitions, improved earnings, and a strengthened balance sheet.

Magontec Limited has reversed its recent losses with a 63% jump in half-year gross profit to $8.5 million and a net profit after tax of $1.1 million, driven by strong demand in electronic anodes and magnesium alloys.

Teaminvest Private Group (ASX: TIP) posted a 19% increase in statutory profit for FY26, driven by strong active portfolio growth and disciplined capital allocation, while preparing to acquire Intelligent Investor in an earnings accretive deal.